Predicting the response to neoadjuvant therapy for early-stage breast cancer: tumor-, blood-, and imaging-related biomarkers

References

• SiegelRLMillerKDJemalACancer statistics, 2017CA: A Cancer Journal for Clinicians201767173028055103
   PubMed Web of Science ®Google Scholar
• ChenWZhengRBaadePDCancer statistics in China, 2015CA: A Cancer Journal for Clinicians201666211513226808342
   PubMed Web of Science ®Google Scholar
• PeartOBreast intervention and breast cancer treatment optionsRadiol Technol2015865quiz 559–562535M555825995404
   PubMedGoogle Scholar
• CianfroccaMGoldsteinLJPrognostic and Predictive Factors in Early-Stage Breast CancerOncologist20049660661615561805
   PubMed Web of Science ®Google Scholar
• SawyersCLThe cancer biomarker problemNature2008452718754855218385728
   PubMed Web of Science ®Google Scholar
• KaufmannMvon MinckwitzGMamounasEPRecommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancerAnnals of Surgical Oncology20121951508151622193884
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trialsLancet Oncol2018191273929242041
   PubMed Web of Science ®Google Scholar
• RubovszkyGHorváthZRecent Advances in the Neoadjuvant Treatment of Breast CancerJ Breast Cancer201720211913128690648
   PubMed Web of Science ®Google Scholar
• KaufmannMPusztaiLUse of standard markers and incorporation of molecular markers into breast cancer therapy: Consensus recommendations from an International Expert PanelCancer201111781575158221472705
   PubMed Web of Science ®Google Scholar
• HarrisLNIsmailaNMcshaneLMUse of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice GuidelineJ Clin Oncol201634101134115026858339
   PubMed Web of Science ®Google Scholar
• BrandtALorenzo BermejoJSundquistJHemminkiKBreast cancer risk in women who fulfill high-risk criteria: at what age should surveillance start?Breast Cancer Res Treat2010121113314119641988
   PubMed Web of Science ®Google Scholar
• CoatesASWinerEPGoldhirschATailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015Ann Oncol20152681533154625939896
   PubMed Web of Science ®Google Scholar
• CuriglianoGBursteinHJP WinerEDe-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017Ann Oncol20172881700171228838210
   PubMed Web of Science ®Google Scholar
• LoiblSJackischCLedererBOutcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trialsBreast Cancer Res Treat2015152237738726109347
   PubMed Web of Science ®Google Scholar
• ElsamanySAlzahraniAAbozeedWNMammographic breast density: Predictive value for pathological response to neoadjuvant chemotherapy in breast cancer patientsBreast201524557658126071795
   PubMed Web of Science ®Google Scholar
• RugoHSBrufskyAMUlcickas YoodMRacial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancerBreast Cancer Res Treat2013141346147024062208
   PubMed Web of Science ®Google Scholar
• GaoJJSwainSMLuminal A Breast Cancer and Molecular Assays: A ReviewOncologist201823555656529472313
   PubMed Web of Science ®Google Scholar
• Llombart-CussacACortésJParéLHER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trialLancet Oncol201718454555428238593
   PubMed Web of Science ®Google Scholar
• LoiblSO’ShaughnessyJUntchMAddition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trialLancet Oncol201819449750929501363
   PubMed Web of Science ®Google Scholar
• BalmativolaDMarchiòCMauleMPathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional studyBreast Cancer Res Treat2014148351152325395316
   PubMed Web of Science ®Google Scholar
• MaioranoEReganMMVialeGPrognostic and predictive impact of central necrosis and fibrosis in early breast cancer: Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapyBreast Cancer Res Treat2010121121121819280340
   PubMed Web of Science ®Google Scholar
• BuhmeidaAAl-MaghrabiJMerdadAPrognostic value of mitotic counts in breast cancer of Saudi Arabian patientsAnticancer Res20113119710321273586
   PubMed Web of Science ®Google Scholar
• PetricMMartinezSAcevedoFCorrelation between Ki67 and Histological Grade in Breast Cancer Patients Treated with Preoperative ChemotherapyAsian Pacific Journal of Cancer Prevention201515231027710280
   Google Scholar
• MacchiaGGambacortaMAMasciocchiCTime to surgery and pathologic complete response after neoadjuvant chemoradiation in rectal cancer: A population study on 2094 patientsClin Transl Radiat Oncol2017481429594202
   PubMedGoogle Scholar
• CortazarPZhangLUntchMPathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisLancet2014384993816417224529560
   PubMed Web of Science ®Google Scholar
• CortazarPGeyerCEPathological Complete Response in Neoadjuvant Treatment of Breast CancerAnn Surg Oncol20152251441144625727556
   PubMed Web of Science ®Google Scholar
• HoussamiNMacaskillPvon MinckwitzGMarinovichMLMamounasEMeta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapyEur J Cancer201248183342335422766518
   PubMed Web of Science ®Google Scholar
• von MinckwitzGUntchMBlohmerJUDefinition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypesJ Clin Oncol201230151796180422508812
   PubMed Web of Science ®Google Scholar
• MazouniCPeintingerFWan-KauSResidual Ductal Carcinoma In Situ in Patients With Complete Eradication of Invasive Breast Cancer After Neoadjuvant Chemotherapy Does Not Adversely Affect Patient OutcomeJournal of Clinical Oncology200725192650265517602071
   PubMed Web of Science ®Google Scholar
• FungFCornacchiSDVanniyasingamTPredictors of 5-year local, regional, and distant recurrent events in a population-based cohort of breast cancer patientsAm J Surg2017213241842527424042
   PubMed Web of Science ®Google Scholar
• RakhaEAEl-SayedMEMenonSGreenARLeeAHSEllisIOHistologic grading is an independent prognostic factor in invasive lobular carcinoma of the breastBreast Cancer Res Treat2008111112112717929165
   PubMed Web of Science ®Google Scholar
• Alvarado-CabreroIAlderete-VázquezGQuintal-RamírezMPatiñoMRuízEIncidence of pathologic complete response in women treated with preoperative chemotherapy for locally advanced breast cancer: correlation of histology, hormone receptor status, Her2/Neu, and gross pathologic findingsAnn Diagn Pathol200913315115719433292
   PubMed Web of Science ®Google Scholar
• GiulianoAEConnollyJLEdgeSBBreast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manualCA: A Cancer Journal for Clinicians201767429030328294295
   PubMed Web of Science ®Google Scholar
• RavelliAReubenJMLanzaFBreast cancer circulating biomarkers: advantages, drawbacks, and new insightsTumor Biology20153696653666526307395
   PubMedGoogle Scholar
• BielčikováZJakabováAPinkasMZemanováMKološtováKBobekVCirculating tumor cells: what we know, what do we want to know about them and are they ready to be used in clinics?Am J Transl Res2017962807282328670371
   PubMed Web of Science ®Google Scholar
• ZhouFZhouYDongJTanWCirculating endothelial cells and their subsets: novel biomarkers for cancerBiomark Med2017118665676
   PubMed Web of Science ®Google Scholar
• CristofanilliMBuddGTEllisMJCirculating Tumor Cells, Disease Progression, and Survival in Metastatic Breast CancerN Engl J Med Overseas Ed20043518781791
   PubMed Web of Science ®Google Scholar
• BidardFCVincent-SalomonASigal-ZafraniBPrognosis of women with stage IV breast cancer depends on detection of circulating tumor cells rather than disseminated tumor cellsAnn Oncol200819349650018187488
   PubMed Web of Science ®Google Scholar
• BuddGTCristofanilliMEllisMJCirculating tumor cells versus imaging--predicting overall survival in metastatic breast cancerClin Cancer Res200612216403640917085652
   PubMed Web of Science ®Google Scholar
• PiergaJYHajageDBachelotTHigh independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patientsAnn Oncol201223361862421642515
   PubMed Web of Science ®Google Scholar
• TewesMAktasBWeltAMolecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapiesBreast Cancer Res Treat2009115358159018679793
   PubMed Web of Science ®Google Scholar
• FalckA-KBendahlP-OIngvarCAnalysis of and prognostic information from disseminated tumour cells in bone marrow in primary breast cancer: a prospective observational studyBMC Cancer201212140322963449
   PubMedGoogle Scholar
• DomschkeCDielIJEnglertSPrognostic Value of Disseminated Tumor Cells in the Bone Marrow of Patients with Operable Primary Breast Cancer: A Long-term Follow-up StudyAnn Surg Oncol20132061865187123263703
   PubMed Web of Science ®Google Scholar
• HartkopfADWallwienerMFehmTNDisseminated tumor cells from the bone marrow of patients with nonmetastatic primary breast cancer are predictive of locoregional relapseAnn Oncol20152661155116025791636
   PubMed Web of Science ®Google Scholar
• HallCKrishnamurthySLodhiADisseminated tumor cells predict survival after neoadjuvant therapy in primary breast cancerCancer2012118234234821717428
   PubMed Web of Science ®Google Scholar
• MathiesenRRBorgenERenolenAPersistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survivalBreast Cancer Research2012144R11722889108
   PubMed Web of Science ®Google Scholar
• PiergaJYBidardFCAutretACirculating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumabAnna Oncol2017281103109
   PubMed Web of Science ®Google Scholar
• BidardFCMichielsSRiethdorfSCirculating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysisJ Natl Cancer Inst2018110656056729659933
   PubMedGoogle Scholar
• IgnatiadisMDawsonSJCirculating tumor cells and circulating tumor DNA for precision medicine: dream or reality?Ann Oncol201425122304231325336116
   PubMed Web of Science ®Google Scholar
• JueckstockJRackBFriedlTWPDetection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer – Results of the German SUCCESS-A- trialBMC Cancer201616140127387743
   PubMedGoogle Scholar
• GormallyECabouxEVineisPHainautPCirculating free DNA in plasma or serum as biomarker of carcinogenesis: Practical aspects and biological significanceMutation Research/Reviews in Mutation Research20076352–3105117
   PubMed Web of Science ®Google Scholar
• CaiCGuoZCaoYZhangWChenYA dual biomarker detection platform for quantitating circulating tumor DNA (ctDNA)Nanotheranostics201821122029291160
   PubMedGoogle Scholar
• JahrSHentzeHEnglischSDNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cellsCancer Res20016141659166511245480
   PubMed Web of Science ®Google Scholar
• SchwarzenbachHPantelKCirculating DNA as biomarker in breast cancerBreast Cancer Research201517113626453190
   PubMedGoogle Scholar
• FumagalliDVenetDIgnatiadisMRNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical TrialJAMA Oncol201732227234
   PubMed Web of Science ®Google Scholar
• JacquesNVimondNConfortiRQuantification of circulating mature endothelial cells using a whole blood four-color flow cytometric assayJ Immunol Methods2008337213214318662694
   PubMed Web of Science ®Google Scholar
• WoywodtABlannADKirschTIsolation and enumeration of circulating endothelial cells by immunomagnetic isolation: proposal of a definition and a consensus protocolJ Thromb Haemost20064367167716460450
   PubMed Web of Science ®Google Scholar
• ZhouFZhouYYangMWenJDongJTanWOptimized multipara-metric flow cytometric analysis of circulating endothelial cells and their subpopulations in peripheral blood of patients with solid tumors: a technical analysisCancer Management and Research20181044746429563835
   PubMed Web of Science ®Google Scholar
• KuoY-HLinC-HShauW-YDynamics of circulating endothelial cells and endothelial progenitor cells in breast cancer patients receiving cytotoxic chemotherapyBMC Cancer201212162023268621
   PubMedGoogle Scholar
• TsujiWIshiguroHTanakaSTakeuchiMUenoTToiMOrally administered S-1 suppresses circulating endothelial cell counts in metastatic breast cancer patientsInt J Clin Oncol201419345245923739924
   PubMed Web of Science ®Google Scholar
• GoonPKLipGYStonelakePSBlannADCirculating endothelial cells and circulating progenitor cells in breast cancer: relationship to endothelial damage/dysfunction/apoptosis, clinicopathologic factors, and the Nottingham Prognostic IndexNeoplasia200911877177919649207
   PubMed Web of Science ®Google Scholar
• AliAMUenoTTanakaSDetermining circulating endothelial cells using CellSearch system during preoperative systemic chemotherapy in breast cancer patientsEur J Cancer201147152265227221737256
   PubMed Web of Science ®Google Scholar
• BotelhoMCAlvesHEndothelial Progenitor Cells in Breast CancerInt J Immunother Cancer Res201621226878074
   PubMedGoogle Scholar
• GingrasISalgadoRIgnatiadisMLiquid biopsy: will it be the ‘magic tool’ for monitoring response of solid tumors to anticancer therapies?Curr Opin Oncol201527656056726335664
   PubMed Web of Science ®Google Scholar
• LowesLBratmanSDittamoreRCirculating Tumor Cells (CTC) and Cell-Free DNA (cfDNA) Workshop 2016: Scientific Opportunities and Logistics for Cancer Clinical Trial IncorporationInt J Mol Sci20161791505
   PubMed Web of Science ®Google Scholar
• O’HanlonDMKerinMJKentPMaherDGrimesHGivenHFAn evaluation of preoperative CA 15-3 measurement in primary breast carcinomaBr J Cancer1995716128812917779725
   PubMed Web of Science ®Google Scholar
• UeharaMKinoshitaTHojoTAkashi-TanakaSIwamotoEFukutomiTLong-term prognostic study of carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) in breast cancerInt J Clin Oncol200813544745118946756
   PubMed Web of Science ®Google Scholar
• ParkBWOhJWKimJHPreoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomesAnn Oncol200819467568118037623
   PubMed Web of Science ®Google Scholar
• MoazzezyNFarahanyTZOloomiMBouzariSRelationship between preoperative serum CA 15-3 and CEA levels and clinicopathological parameters in breast cancerAsian Pac J Cancer Prev20141541685168824641390
   PubMedGoogle Scholar
• AtoumMNimerNAbdeldayemSNasrHRelationships among serum CA15-3 tumor marker, TNM staging, and estrogen and progesterone receptor expression in benign and malignant breast lesionsAsian Pac J Cancer Prev201213385786022631661
   PubMedGoogle Scholar
• SamyNRagabHMEl MaksoudNAShaalanMPrognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: A short follow-upCancer Biomarkers201062637220571232
   PubMed Web of Science ®Google Scholar
• FuYLiHAssessing Clinical Significance of Serum CA15-3 and Carcinoembryonic Antigen (CEA) Levels in Breast Cancer Patients: A Meta-AnalysisMed Sci Monit2016223154316227596019
   PubMed Web of Science ®Google Scholar
• HarrisLFritscheHMennelRAmerican Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancerJ Clin Oncol200725335287531217954709
   PubMed Web of Science ®Google Scholar
• HarrisLFritscheHMennelRAmerican Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancerJ Clin Oncol200725335287531217954709
   PubMed Web of Science ®Google Scholar
• NassarFJNasrRTalhoukRMicroRNAs as biomarkers for early breast cancer diagnosis, prognosis and therapy predictionPharmacol Ther2017172344927916656
   PubMed Web of Science ®Google Scholar
• AmorimMSaltaSHenriqueRJerónimoCDecoding the usefulness of non-coding RNAs as breast cancer markersJ Transl Med201614126527629831
   PubMedGoogle Scholar
• IorioMVCasaliniPTagliabueEMénardSCroceCMMicroRNA profiling as a tool to understand prognosis, therapy response and resistance in breast cancerEur J Cancer200844182753275919022662
   PubMed Web of Science ®Google Scholar
• MarkouAYousefGMStathopoulosEGeorgouliasVLianidouEPrognostic Significance of Metastasis-Related MicroRNAs in Early Breast Cancer Patients with a Long Follow-upClin Chem201460119720524132943
   PubMed Web of Science ®Google Scholar
• D’AiutoFCallariMDugoMmiR-30e* is an independent subtype-specific prognostic marker in breast cancerBr J Cancer2015113229029826057454
   PubMed Web of Science ®Google Scholar
• BaileySTWesterlingTBrownMLoss of Estrogen-Regulated microRNA Expression Increases HER2 Signaling and Is Prognostic of Poor Outcome in Luminal Breast CancerCancer Res201575243644525388283
   PubMed Web of Science ®Google Scholar
• GodinhoMFESieuwertsAMLookMPRelevance of BCAR4 in tamoxifen resistance and tumour aggressiveness of human breast cancerBr J Cancer201010381284129120859285
   PubMed Web of Science ®Google Scholar
• ChenY-MLiuYWeiH-YLvK-ZFuPLinc-ROR induces epithelial-mesenchymal transition and contributes to drug resistance and invasion of breast cancer cellsTumor Biology2016378108611087026883251
   PubMedGoogle Scholar
• PaikSShakSTangGA Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerN Engl J Med Overseas Ed20043512728172826
   PubMed Web of Science ®Google Scholar
• PaikSTangGShakSGene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancerJ Clin Oncol200624233726373416720680
   PubMed Web of Science ®Google Scholar
• SparanoJAGrayRJMakowerDFProspective Validation of a 21-Gene Expression Assay in Breast CancerN Engl J Med Overseas Ed20153732120052014
   PubMed Web of Science ®Google Scholar
• AlbainKSBarlowWEShakSPrognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trialLancet Oncol2010111556520005174
   PubMed Web of Science ®Google Scholar
• GluzONitzUAChristgenMWest German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology AssessmentJ Clin Oncol201634202341234926926676
   PubMed Web of Science ®Google Scholar
• van ‘t VeerLJDaiHvan de VijverMJGene expression profiling predicts clinical outcome of breast cancerNature2002415687153053611823860
   PubMed Web of Science ®Google Scholar
• van de VijverMJHeYDvan ‘t VeerLJA Gene-Expression Signature as a Predictor of Survival in Breast CancerN Engl J Med Overseas Ed20023472519992009
   PubMed Web of Science ®Google Scholar
• EstevaFJSahinAACristofanilliMPrognostic Role of a Multigene Reverse Transcriptase-PCR Assay in Patients with Node-Negative Breast Cancer Not Receiving Adjuvant Systemic TherapyClinical Cancer Research20051193315331915867229
   PubMed Web of Science ®Google Scholar
• CardosoFvan’t VeerLJBogaertsJ70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast CancerN Engl J Med Overseas Ed20163758717729
   PubMed Web of Science ®Google Scholar
• DuffyMJHarbeckNNapMClinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM)Eur J Cancer20177528429828259011
   PubMed Web of Science ®Google Scholar
• GnantMFilipitsMGreilRPredicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy aloneAnn Oncol201425233934524347518
   PubMed Web of Science ®Google Scholar
• ParkerJSMullinsMCheangMCSupervised risk predictor of breast cancer based on intrinsic subtypesJ Clin Oncol20092781160116719204204
   PubMed Web of Science ®Google Scholar
• FilipitsMRudasMJakeszRA New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk FactorsClinical Cancer Research201117186012602021807638
   PubMed Web of Science ®Google Scholar
• ZhangYSchnabelCASchroederBEBreast Cancer Index Identifies Early-Stage Estrogen Receptor-Positive Breast Cancer Patients at Risk for Early- and Late-Distant RecurrenceClinical Cancer Research201319154196420523757354
   PubMed Web of Science ®Google Scholar
• DemariaSPikarskyEKarinMCancer and inflammation: promise for biologic therapyJ Immunother201033433535120386472
   PubMed Web of Science ®Google Scholar
• MohmeMRiethdorfSPantelKCirculating and disseminated tumour cells — mechanisms of immune surveillance and escapeNat Rev Clin Oncol201714315516727644321
   PubMed Web of Science ®Google Scholar
• MittalDGubinMMSchreiberRDSmythMJNew insights into cancer immunoediting and its three component phases—elimination, equilibrium and escapeCurr Opin Immunol201427162524531241
   PubMed Web of Science ®Google Scholar
• ChoiJGyamfiJJangHKooJSThe role of tumor-associated macrophage in breast cancer biologyHistol Histopathol201711916
   Google Scholar
• AnaniWShurinMRTargeting Myeloid-Derived Suppressor Cells in CancerAdv Exp Med Biol2017103610512829275468
   PubMed Web of Science ®Google Scholar
• WargoJAReubenACooperZAOhKSSullivanRJImmune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With ImmunotherapySemin Oncol201542460161626320064
   PubMed Web of Science ®Google Scholar
• SavasPSalgadoRDenkertCClinical relevance of host immunity in breast cancer: from TILs to the clinicNat Rev Clin Oncol201613422824126667975
   PubMed Web of Science ®Google Scholar
• SalgadoRDenkertCDemariaSThe evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014Ann Oncol201526225927125214542
   PubMed Web of Science ®Google Scholar
• SimonRMPaikSHayesDFUse of Archived Specimens in Evaluation of Prognostic and Predictive BiomarkersJNCI Journal of the National Cancer Institute2009101211446145219815849
   PubMed Web of Science ®Google Scholar
• SeoANLeeHJKimEJTumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancerBr J Cancer2013109102705271324129232
   PubMed Web of Science ®Google Scholar
• SalgadoRDenkertCCampbellCTumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and TrastuzumabJAMA Oncol20151444845426181252
   PubMed Web of Science ®Google Scholar
• AliHRProvenzanoEDawsonS-JAssociation between CD8+ T-cell infiltration and breast cancer survival in 12 439 patientsAnnals of Oncology20142581536154324915873
   PubMed Web of Science ®Google Scholar
• LoiSSirtaineNPietteFPrognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98J Clin Oncol201331786086723341518
   PubMed Web of Science ®Google Scholar
• DenkertCvon MinckwitzGDarb-EsfahaniSTumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapyLancet Oncol2018191405029233559
   PubMed Web of Science ®Google Scholar
• LewisCEPollardJWDistinct Role of Macrophages in Different Tumor MicroenvironmentsCancer Res200666260561216423985
   PubMed Web of Science ®Google Scholar
• MantovaniAMarchesiFMalesciALaghiLAllavenaPTumour-associated macrophages as treatment targets in oncologyNat Rev Clin Oncol201714739941628117416
   PubMed Web of Science ®Google Scholar
• BiswasSKAllavenaPMantovaniATumor-associated macrophages: functional diversity, clinical significance, and open questionsSemin Immunopathol201335558560023657835
   PubMed Web of Science ®Google Scholar
• ZhaoXQuJSunYPrognostic significance of tumor-associated macrophages in breast cancer: a meta-analysis of the literatureOncotarget2017818305763058628427165
   PubMedGoogle Scholar
• ParkK-YLiGPlattMOMonocyte-derived macrophage assisted breast cancer cell invasion as a personalized, predictive metric to score metastatic riskSci Rep2015511385526349896
   PubMedGoogle Scholar
• GabrilovichDINagarajSMyeloid-derived suppressor cells as regulators of the immune systemNat Rev Immunol20099316217419197294
   PubMed Web of Science ®Google Scholar
• CondamineTGabrilovichDIMolecular mechanisms regulating myeloid-derived suppressor cell differentiation and functionTrends Immunol2011321192521067974
   PubMed Web of Science ®Google Scholar
• ToorSMSyed KhajaASEl SalhatHMyeloid cells in circulation and tumor microenvironment of breast cancer patientsCancer Immunology, Immunotherapy201766675376428283696
   PubMed Web of Science ®Google Scholar
• Diaz-MonteroCMSalemMLNishimuraMIGarrett-MayerEColeDJMonteroAJIncreased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapyCancer Immunology, Immunotherapy2009581495918446337
   PubMed Web of Science ®Google Scholar
• WesolowskiRDugganMCStiffACirculating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancerCancer Immunology, Immunotherapy201766111437144728688082
   PubMed Web of Science ®Google Scholar
• LebienTWTedderTFB lymphocytes: how they develop and functionBlood200811251570158018725575
   PubMed Web of Science ®Google Scholar
• BrownJRWimberlyHLanninDRNixonCRimmDLBossuytVMultiplexed Quantitative Analysis of CD3, CD8, and CD20 Predicts Response to Neoadjuvant Chemotherapy in Breast CancerClinical Cancer Research201420235995600525255793
   PubMed Web of Science ®Google Scholar
• MehrRSternberg-SimonMMichaeliMPickmanYModels and methods for analysis of lymphocyte repertoire generation, development, selection and evolutionImmunol Lett20121481112222902400
   PubMed Web of Science ®Google Scholar
• WangJYangJIdentification of CD4+CD25+CD127− regulatory T cells and CD14+HLA−DR−/low myeloid-derived suppressor cells and their roles in the prognosis of breast cancerBiomed Rep20165220821227446543
   PubMedGoogle Scholar
• DemirLYigitSEllidokuzHPredictive and prognostic factors in locally advanced breast cancer: effect of intratumoral FOXP3+ TregsClin Exp Metastasis20133081047106223836289
   PubMed Web of Science ®Google Scholar
• SageEKSchmidTESedelmayrMComparative analysis of the effects of radiotherapy versus radiotherapy after adjuvant chemotherapy on the composition of lymphocyte subpopulations in breast cancer patientsRadiother Oncol2016118117618026683801
   PubMed Web of Science ®Google Scholar
• SongQRenJZhouXCirculating CD8 + CD28 − suppressor T cells tied to poorer prognosis among metastatic breast cancer patients receiving adoptive T-cell therapy: A cohort studyCytotherapy201820112613328988693
   PubMed Web of Science ®Google Scholar
• SongGWangXJiaJElevated level of peripheral CD8+CD28− T lymphocytes are an independent predictor of progression-free survival in patients with metastatic breast cancer during the course of chemotherapyCancer Immunology, Immunotherapy20136261123113023604172
   PubMed Web of Science ®Google Scholar
• DattaJFracolMMcmillanMTAssociation of Depressed Anti-HER2 T-Helper Type 1 Response With Recurrence in Patients With Completely Treated HER2-Positive Breast CancerJAMA Oncol20162224224626719971
   PubMed Web of Science ®Google Scholar
• DattaJBerkEXuSAnti-HER2 CD4+ T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancerBreast Cancer Research20151717125997452
   PubMedGoogle Scholar
• O’ConnorJPAboagyeEOAdamsJEImaging biomarker roadmap for cancer studiesNat Rev Clin Oncol201714316918627725679
   PubMed Web of Science ®Google Scholar
• ChagparABMiddletonLPSahinAAAccuracy of Physical Examination, Ultrasonography, and Mammography in Predicting Residual Pathologic Tumor Size in Patients Treated With Neoadjuvant ChemotherapyAnn Surg2006243225726416432360
   PubMed Web of Science ®Google Scholar
• FowlerAMMankoffDAJoeBNImaging Neoadjuvant Therapy Response in Breast CancerRadiology2017285235837529045232
   PubMed Web of Science ®Google Scholar
• CroshawRShapiro-WrightHSvenssonEErbKJulianTAccuracy of Clinical Examination, Digital Mammogram, Ultrasound, and MRI in Determining Postneoadjuvant Pathologic Tumor Response in Operable Breast Cancer PatientsAnn Surg Oncol201118113160316321947594
   PubMed Web of Science ®Google Scholar
• KeuneJDJeffeDBSchootmanMHoffmanAGillandersWEAftRLAccuracy of ultrasonography and mammography in predicting pathologic response after neoadjuvant chemotherapy for breast cancerAm J Surg2010199447748420359567
   PubMed Web of Science ®Google Scholar
• HeineJJMalhotraPTissueMbreast cancer risk, serial image analysis, and digital mammography. Part 1. Tissue and related risk factorsAcad Radiol20029329831611887946
   PubMed Web of Science ®Google Scholar
• JafariSHSaadatpourZSalmaninejadABreast cancer diagnosis: Imaging techniques and biochemical markersJ Cell Physiol201823375200521329219189
   PubMed Web of Science ®Google Scholar
• SchellingMAvrilNNährigJPositron emission tomography using [18F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancerJ Clin Oncol20001881689169510764429
   PubMed Web of Science ®Google Scholar
• LeeHWLeeHMChoiSEThe Prognostic Impact of Early Change in 18F-FDG PET SUV After Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast CancerJ Nucl Med20165781183118827033896
   PubMed Web of Science ®Google Scholar
• Dose SchwarzJBaderMJenickeLHemmingerGJänickeFAvrilNEarly prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PETJ Nucl Med20054671144115016000283
   PubMed Web of Science ®Google Scholar
• KostakogluLDuanFIdowuMOA Phase II Study of 3’-Deoxy-3’-18F-Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688J Nucl Med201556111681168926359256
   PubMed Web of Science ®Google Scholar
• LindholmPLapelaMNågrenKLehikoinenPMinnHJyrkkiöSPreliminary study of carbon-11 methionine PET in the evaluation of early response to therapy in advanced breast cancerNucl Med Commun2009301303619306512
   PubMed Web of Science ®Google Scholar
• KennyLMContractorKBHinzRReproducibility of [11C] choline-positron emission tomography and effect of trastuzumabClin Cancer Res201016164236424520682702
   PubMed Web of Science ®Google Scholar
• UlanerGAGoldmanDACorbenAProspective Clinical Trial of 18F-Fluciclovine PET/CT for Determining the Response to Neoadjuvant Therapy in Invasive Ductal and Invasive Lobular Breast CancersJ Nucl Med20175871037104227856630
   PubMed Web of Science ®Google Scholar
• PinkerKHelbichTHMorrisEAThe potential of multiparametric MRI of the breastBr J Radiol20179010692016071527805423
   PubMed Web of Science ®Google Scholar
• MariscottiGHoussamiNDurandoMAccuracy of mammography, digital breast tomosynthesis, ultrasound and MR imaging in preoperative assessment of breast cancerAnticancer Res20143431219122524596363
   PubMed Web of Science ®Google Scholar
• LobbesMBIPrevosRSmidtMThe role of magnetic resonance imaging in assessing residual disease and pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy: a systematic reviewInsights Imaging20134216317523359240
   PubMedGoogle Scholar
• YuanYChenXSLiuSYShenKWAccuracy of MRI in prediction of pathologic complete remission in breast cancer after preoperative therapy: a meta-analysisAJR Am J Roentgenol2010195126026820566826
   PubMed Web of Science ®Google Scholar
• MarinovichMLHoussamiNMacaskillPMeta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapyJ Natl Cancer Inst2013105532133323297042
   PubMedGoogle Scholar
• YlGPanSMRenJYangZXJiangGQRole of Magnetic Resonance Imaging in Detection of Pathologic Complete Remission in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: A Meta-analysisClin Breast Cancer201717424525528209330
   PubMed Web of Science ®Google Scholar
• MarinoMAHelbichTBaltzerPPinker-DomenigKMultiparametric MRI of the breast: A reviewJ Magn Reson Imaging201847230131528639300
   PubMed Web of Science ®Google Scholar
• MarinovichMLSardanelliFCiattoSEarly prediction of pathologic response to neoadjuvant therapy in breast cancer: Systematic review of the accuracy of MRIBreast201221566967722863284
   PubMed Web of Science ®Google Scholar
• PrevosRSmidtMLTjan-HeijnenVCGPre-treatment differences and early response monitoring of neoadjuvant chemotherapy in breast cancer patients using magnetic resonance imaging: a systematic reviewEur Radiol201222122607261622983282
   PubMed Web of Science ®Google Scholar
• WoolfDKPadhaniARTaylorNJAssessing response in breast cancer with dynamic contrast-enhanced magnetic resonance imaging: Are signal intensity–time curves adequate?Breast Cancer Res Treat2014147233534325129341
   PubMed Web of Science ®Google Scholar
• LiSPMakrisABeresfordMJUse of dynamic contrast-enhanced MR imaging to predict survival in patients with primary breast cancer undergoing neoadjuvant chemotherapyRadiology20112601687821502383
   PubMed Web of Science ®Google Scholar
• RaunigDLMcshaneLMPennelloGQuantitative imaging biomarkers: A review of statistical methods for technical performance assessmentStat Methods Med Res2015241276724919831
   PubMed Web of Science ®Google Scholar
• PartridgeSCMcdonaldESDiffusion weighted magnetic resonance imaging of the breast: protocol optimization, interpretation, and clinical applicationsMagn Reson Imaging Clin N Am201321360162423928248
   PubMed Web of Science ®Google Scholar
• ParkSHMoonWKChoNDiffusion-weighted MR Imaging: Pretreatment Prediction of Response to Neoadjuvant Chemotherapy in Patients with Breast CancerRadiology20102571566320851939
   PubMed Web of Science ®Google Scholar
• BelliPCostantiniMIerardiCDiffusion-weighted Imaging in Evaluating the Response to Neoadjuvant Breast Cancer TreatmentBreast J201117661061921929557
   PubMed Web of Science ®Google Scholar
• WuLMHuJNGuHYHuaJChenJXuJRCan diffusion-weighted MR imaging and contrast-enhanced MR imaging precisely evaluate and predict pathological response to neoadjuvant chemotherapy in patients with breast cancer?Breast Cancer Res Treat20121351172822476850
   PubMed Web of Science ®Google Scholar
• SardanelliFCarbonaroLAMontemezziSCavedonCTrimboliRMClinical Breast MR Using MRS or DWI: Who Is the Winner?Front Oncol20166Suppl 121727840809
   PubMedGoogle Scholar
• JagannathanNRKumarMSeenuVEvaluation of total choline from in-vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancerBr J Cancer20018481016102211308247
   PubMed Web of Science ®Google Scholar
• MeisamySBolanPJBakerEHNeoadjuvant Chemotherapy of Locally Advanced Breast Cancer: Predicting Response with in Vivo 1H MR Spectroscopy—A Pilot Study at 4 TRadiology2004233242443115516615
   PubMed Web of Science ®Google Scholar
• BaekHMChenJHNalciogluOSuMYMySProton MR spectroscopy for monitoring early treatment response of breast cancer to neo-adjuvant chemotherapyAnn Oncol20081951022102418372283
   PubMed Web of Science ®Google Scholar
• YamaguchiKNakazonoTEgashiraRDiagnostic Performance of Diffusion Tensor Imaging with Readout-segmented Echo-planar Imaging for Invasive Breast Cancer: Correlation of ADC and FA with Pathological Prognostic MarkersMagn Reson Med Sci201716324525227853053
   PubMed Web of Science ®Google Scholar
• Furman-HaranENissanNRicart-SelmaVMartinez-RubioCDeganiHCamps-HerreroJQuantitative evaluation of breast cancer response to neoadjuvant chemotherapy by diffusion tensor imaging: Initial resultsJ Magn Reson Imaging2017
   PubMed Web of Science ®Google Scholar
• FanMWuGChengHZhangJShaoGLiLRadiomic analysis of DCE-MRI for prediction of response to neoadjuvant chemotherapy in breast cancer patientsEur J Radiol20179414014728712700
   PubMed Web of Science ®Google Scholar
• LambinPLeijenaarRTHDeistTMRadiomics: the bridge between medical imaging and personalized medicineNat Rev Clin Oncol2017141274976228975929
   PubMed Web of Science ®Google Scholar
• WangJKatoFOyama-ManabeNIdentifying Triple-Negative Breast Cancer Using Background Parenchymal Enhancement Heterogeneity on Dynamic Contrast-Enhanced MRI: A Pilot Radiomics StudyPLoS One20151011e014330826600392
   PubMed Web of Science ®Google Scholar
• WuJGongGCuiYLiRIntratumor partitioning and texture analysis of dynamic contrast-enhanced (DCE)-MRI identifies relevant tumor subregions to predict pathological response of breast cancer to neoadjuvant chemotherapyJ Magn Reson Imaging20164451107111527080586
   PubMed Web of Science ®Google Scholar
• FanMChengHZhangPDCE-MRI texture analysis with tumor subregion partitioning for predicting Ki-67 status of estrogen receptor-positive breast cancersJ Magn Reson Imaging201848123724729219225
   PubMed Web of Science ®Google Scholar
• HaSParkSBangJ-IKimE-KLeeH-YMetabolic Radiomics for Pretreatment 18F-FDG PET/CT to Characterize Locally Advanced Breast Cancer: Histopathologic Characteristics, Response to Neoadjuvant Chemotherapy, and PrognosisSci Rep201771155628484211
   PubMedGoogle Scholar
• ParkHLimYKoESEsKRadiomics Signature on Magnetic Resonance Imaging: Association with Disease-Free Survival in Patients with Invasive Breast CancerClinical Cancer Research Epub2018618
   Web of Science ®Google Scholar
• EisenhauerEATherassePBogaertsJNew response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)Eur J Cancer200945222824719097774
   PubMed Web of Science ®Google Scholar
• SeymourLBogaertsJPerroneAiRECIST: guidelines for response criteria for use in trials testing immunotherapeuticsLancet Oncol2017183e143e15228271869
   PubMed Web of Science ®Google Scholar
• WahlRLJaceneHKasamonYLodgeMAFrom RECIST to PER-CIST: Evolving Considerations for PET response criteria in solid tumorsJ Nucl Med200950Suppl 1122S15019403881
   PubMed Web of Science ®Google Scholar
• WeaverOLeungJWTBiomarkers and Imaging of Breast CancerAJR Am J Roentgenol2018210227127829166151
   PubMed Web of Science ®Google Scholar
• LiHZhuYBurnsideESMR Imaging Radiomics Signatures for Predicting the Risk of Breast Cancer Recurrence as Given by Research Versions of MammaPrint, Oncotype DX, and PAM50 Gene AssaysRadiology2016281238239127144536
   PubMed Web of Science ®Google Scholar
• PinkerKShitanoFSalaEBackground, current role, and potential applications of radiogenomicsJ Magn Reson Imaging201847360462029095543
   PubMed Web of Science ®Google Scholar
• CxMGaoFLuoJNeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast CancerClinical cancer research: an official journal of the American Association for Cancer Research201723154055406528270497
   PubMed Web of Science ®Google Scholar
• JovanovićBMayerIAMayerELA Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67Clinical Cancer Research201723154035404528270498
   PubMed Web of Science ®Google Scholar
• CuriglianoGRomieuGCamponeMA phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancerBreast Cancer Res Treat2016156230131026975189
   PubMed Web of Science ®Google Scholar
• SturgeonCHillRHortinGLThompsonDTaking a new biomarker into routine use - A perspective from the routine clinical biochemistry laboratoryProteomics Clin Appl201041289290321137030
   PubMed Web of Science ®Google Scholar